Trial Profile
An Investigator Sponsored Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses Followed by Dose Expansion of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Asian Patients With Advanced or Metastatic Solid Tumor Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Apr 2021
Price :
$35
*
At a glance
- Drugs Selinexor (Primary)
- Indications Advanced breast cancer; B-cell lymphoma; Carcinoma; Cholangiocarcinoma; Colorectal cancer; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Gastric cancer; Gynaecological cancer; Head and neck cancer; Hodgkin's disease; Liver cancer; Lung cancer; Malignant thymoma; Nasopharyngeal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Tongue cancer
- Focus Adverse reactions
- 02 Mar 2021 Results presented at the 19th International Congress on Targeted Anticancer Therapies.
- 08 Sep 2020 Status changed from recruiting to completed.
- 11 Oct 2016 Results (N=18) of colorectal cancer patients presented at the 41st European Society for Medical Oncology Congress.